4.7 Meeting Abstract

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study

Journal

BLOOD
Volume 128, Issue 22, Pages -

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.V128.22.1147.1147

Keywords

-

Categories

Funding

  1. Bristol-Meyers Squibb
  2. Bioinvent
  3. Novartis
  4. Millennium
  5. Acetylon
  6. Glaxo Smith Kline
  7. Calithera
  8. Janssen
  9. Johnson Johnson
  10. Pfizer

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available